Histogenics Corporation (HSGX) Insiders Selling At Fast Rate

The surge in insider buying at Histogenics Corporation (NASDAQ:HSGX) is picking up steam with the 12-month sell/buy ratio now at 0 to 1. HSGX corporate insiders offloaded no shares over a year when buyers snapped up 1,309,688 shares in the same time frame.

Gridley Adam gathered a total of 2 thousand shares of Histogenics Corporation (HSGX) at average share price of $2.15. This insider trade in the company took place on 05/16/2018. The total for the purchase was set at $4.3 thousand. After this transaction, the President and CEO account balance stood at 7 thousand shares. The stock lost -92.09 percent since that insider purchase. On 08/16/2017, Gill David N, Director, purchased 3 thousand shares at a price per share of $1.81. This added 5.43 thousand shares to the insider’s fortune and the stock saw a -90.61 percent retreat in value since the news became public. This transaction left 14 thousand shares in the Director account.

On 05/16/2017, Director Gill David N performed a purchase transaction worth $5.04 thousand. This purchase at $1.68 each has added 3 thousand shares into the insider’s portfolio position. Meanwhile, shares have recorded -89.88 percent decrease since the transaction was reported. The insider now is left with 11 thousand shares remaining in the account. Gill David N, who performs the Director job, bought 3 thousand shares for $4.95 thousand. The acquisition occurred on 12/15/2016 was priced at $1.65 per share. The share price plunged -89.7 percent since the reporting date. Gill David N now left with a stake of 8 thousand HSGX stock worth $1.36 thousand after the insider buying.

The 12-month median price target for Histogenics Corporation (HSGX) assigned by the analysts stands at $1.35, which represents a return potential of 694.12 percent when compared to the closing price of the stock of $0.17 on Friday, January 11. The lowest price target for the stock is $1.2 — slightly more than 605.88 percent from HSGX’s current share price. The stock will probably climb 1811.76 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $1.5-month high price target. This represents a whopping 782.35 percent increase from where shares are trading today.

On momentum oscillators front, ‘RSI’ has touched 35.53 on daily chart, which may remain a cause for comfort. If the price breaks below $0.14 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $0.18 mark may result into a pull-back move towards $0.19 level. The stock is currently hovering around the first support level of $0.16. Below this, the next support is placed in the zone of $0.14. Till the time, the HSGX stock trades above this level, bulls have nothing to fear.

Shares of Histogenics Corporation (HSGX) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry HSGX operates in has an average P/E of 29.45. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 0 on the Price-to-Sales ratio. Compare this with the industry average P/S of 19.89. 0 percent is the gross profit margin for Histogenics Corporation and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.

On 11th of January, Histogenics Corporation (NASDAQ:HSGX) shares ended lower after a volatile session. The shares dropped -0.01 points or -2.63 percent at $0.17 with a light trade volume of 7.791 million shares. After opening the session at $0.179, the shares went as high as $0.18 and as low as $0.155, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $10.93 million and now has 64.12 million shares outstanding. Histogenics Corporation (HSGX) stock has lost -61.46 percent of market value in 21 trading days.

HSGX stock has a trailing 3-year beta of 2.72, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$0.43 a share in the trailing twelve months. The stock’s value has surged 92.87 percent year to date (YTD) against a decline of -93.57 percent in 12 month’s time. The company’s shares still trade -94.91 percent away from its 1-year high of $3.35 and 113.12 percent up from 52-week low of $0.08. The average consensus rating on the company is 2, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.